Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | PRCP | P42785 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15334650 | 1.00 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL31159189 | 1.00 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL29590929 | 1.00 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL1011182 | 1.00 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL1690518 | 1.00 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CPRCP | |
| Hydrochloric Acid SCHEMBL16412125 | 0.98 | PNMT (0.56) | PNMTADRA2AADRA2BADRA2CPRCP | |
| Hydrochloric Acid SCHEMBL17838213 | 0.98 | PNMT (0.56) | PNMTADRA2AADRA2BADRA2CPRCP | |
| Hydrochloric Acid SCHEMBL29590845 | 0.98 | PNMT (0.56) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL5766795 | 0.80 | HTR2C (0.50) | PNMTADRA2AADRA2BADRA2CPRCP | |
| Hydrochloric Acid SCHEMBL11458153 | 0.78 | HTR2C (0.48) | PNMTADRA2AADRA2BADRA2CPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245699-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| WO-2023161317-A1 | 5-[7-(3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBONYL)-1,2,3,4 TETRAHYDROISOQUINOLIN-6-Y L]-1H-PYRROLE-3-CARBOXAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2023-08-31 | — | — | WO | disclosed |
| CN-109456324-B | Isoindoline or isoquinoline compounds, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-04-22 | — | — | CN | disclosed |
| US-20210290631-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2021-09-23 | — | — | US | disclosed |
| US-11058689-B2 | Pyrrole compounds, a process for their preparation and pharmaceutical | LES LABORATOIRES SERVIER (FR) | 2021-07-13 | — | — | US | disclosed |
| US-11028070-B2 | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2021-06-08 | — | — | US | disclosed |
| US-20200262816-A1 | ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2020-08-20 | — | — | US | disclosed |
| US-20200261464-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2020-08-20 | — | — | US | disclosed |
| US-8716492-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716492-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120088758-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-12 | — | — | US | disclosed |
| US-8101778-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7482361-B2 | Crystalline form for quinapril hydrochloride and process for preparing the same | LUPIN LIMITED (IN) | 2009-01-27 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058689-B2 | Pyrrole compounds, a process for their preparation and pharmaceutical | PDCD11, RRM2B, RRS1 | PNMT 2909/4885ADRA2A 1372/4885ADRA2B 1768/4885 |
| US-20210290631-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDCD11, RRM2, RRM2B | PNMT 2604/4885ADRA2A 1437/4885ADRA2B 2091/4885 |
| US-20120088758-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | PNMT 4870/4885ADRA2A 4416/4885ADRA2B 4472/4885 |
| US-20200261464-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDCD11, RRS1, RRM2B | PNMT 3174/4885ADRA2A 1321/4885ADRA2B 1851/4885 |
| US-20240245699-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDCD11, RRM2B, RRM2 | PNMT 3109/4885ADRA2A 1292/4885ADRA2B 1797/4885 |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | PNMT 1388/4885ADRA2A 4441/4885ADRA2B 4495/4885 |
| US-20200262816-A1 | ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BAX, RECQL, CASP7 | PNMT 1937/4885ADRA2A 686/4885ADRA2B 793/4885 |
| US-11028070-B2 | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | BAX, RECQL, CASP7 | PNMT 1937/4885ADRA2A 686/4885ADRA2B 793/4885 |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | PNMT 4870/4885ADRA2A 4416/4885ADRA2B 4472/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | PNMT 1836/4885ADRA2A 4689/4885ADRA2B 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.